UGL Joint Compound

Product Description

UGL Joint Compound was a drywall finishing product manufactured by United Gilsonite Laboratories (UGL), a specialty chemical and building products company based in Scranton, Pennsylvania. The compound was formulated for use in the installation and finishing of interior gypsum wallboard systems, serving as a bonding and finishing material applied to seams, joints, nail holes, and surface imperfections in drywall construction.

Joint compounds of this era were workhorses of the construction industry. They were applied in multiple coats — a base or “tape” coat, followed by intermediate and finish coats — with sanding required between applications to achieve a smooth, paint-ready surface. UGL marketed its joint compound to professional tradespeople and the broader construction market as a reliable, easy-to-work product suitable for residential and commercial applications.

United Gilsonite Laboratories is perhaps better known for its waterproofing, concrete, and wood-finishing product lines, including the well-known Drylok brand. However, the company also produced a line of drywall finishing products, including joint compounds, that have come under scrutiny due to their historical asbestos content. Like many building product manufacturers of the mid-twentieth century, UGL incorporated asbestos into its formulations during a period when the mineral was widely used across American industry as a reinforcing and texturing agent.

Asbestos Content

UGL Joint Compound has been identified in litigation records as containing chrysotile asbestos. Chrysotile, also referred to as white asbestos, is a serpentine-form fiber that was the most commercially prevalent type of asbestos used in building materials throughout the twentieth century in the United States. Its fine, flexible fibers made it well-suited for incorporation into products where uniform texture, binding strength, and workability were desirable characteristics.

In joint compounds generally, asbestos fibers served several functional purposes: they improved the product’s workability and spreadability, reinforced the dried compound to reduce cracking, and contributed to a smoother texture upon sanding. These properties made asbestos an attractive additive for manufacturers competing in the mid-century construction materials market.

Plaintiffs in litigation have alleged that UGL Joint Compound contained chrysotile asbestos at concentrations sufficient to generate hazardous airborne fiber levels during normal foreseeable use — particularly during the sanding and mixing phases of application. The presence of asbestos in joint compound formulations from this era is consistent with broad industry practice documented across regulatory and litigation records.

Federal regulatory frameworks, including the Environmental Protection Agency’s Asbestos Hazard Emergency Response Act (AHERA) and OSHA’s asbestos standards, have long recognized that chrysotile-containing building materials pose an inhalation hazard when disturbed, and that joint compounds are among the product categories capable of releasing respirable fibers into the breathing zone of workers and bystanders.

How Workers Were Exposed

Litigation records document that workers across multiple trades and work environments were potentially exposed to asbestos-containing dust generated by UGL Joint Compound during ordinary construction and finishing activities. Although industrial workers are among the populations documented in legal proceedings involving this product, exposure was not limited to any single occupation.

The primary mechanism of exposure was airborne fiber release during the sanding of dried joint compound. Sanding — whether performed by hand or with powered equipment — is a dust-generating activity. When joint compound containing chrysotile asbestos was abraded, the bonding matrix was disrupted and asbestos fibers were liberated into the surrounding air. In enclosed or poorly ventilated spaces, these fibers could remain suspended for extended periods, creating sustained inhalation exposure for workers in the immediate area as well as those working nearby.

Plaintiffs alleged that exposure also occurred during the mixing of powdered joint compound formulations. Dry-mix products, when combined with water, generated dust clouds during the pouring and blending process. Workers handling bags of powdered compound, particularly in confined or indoor spaces, could inhale significant quantities of respirable asbestos fibers during this phase of work.

Additional exposure pathways identified in litigation records include:

  • Cleanup and debris removal: Sweeping or collecting sanded compound dust without adequate respiratory protection could mobilize settled fibers back into the air.
  • Bystander exposure: Workers performing other trades in proximity to joint compound finishing operations — electricians, painters, plumbers, and others present on active job sites — could be exposed to fibers generated by drywall finishers working in adjacent areas.
  • Removal and renovation work: In later decades, workers engaged in the demolition or renovation of structures containing previously applied asbestos-containing joint compound faced exposure during the mechanical disturbance of finished wall surfaces.

OSHA’s asbestos permissible exposure limit (PEL) for chrysotile asbestos is 0.1 fibers per cubic centimeter of air, averaged over an eight-hour workday. Research and industrial hygiene documentation from litigation proceedings have consistently shown that sanding joint compound — with or without powered equipment — can generate airborne fiber concentrations well above this threshold in uncontrolled work environments.

UGL Joint Compound is classified as a Tier 2 litigation product. There is no dedicated asbestos trust fund established by United Gilsonite Laboratories for UGL Joint Compound claims. Individuals seeking compensation for asbestos-related illness arising from exposure to this product must pursue claims through the civil tort litigation system rather than through an administrative trust fund claims process.

Litigation records document that plaintiffs have filed civil lawsuits against UGL and related parties alleging injury from exposure to chrysotile asbestos contained in UGL Joint Compound. These cases have typically been brought by individuals diagnosed with asbestos-related diseases including mesothelioma, asbestosis, and lung cancer, as well as their surviving family members in wrongful death actions.

Plaintiffs alleged that United Gilsonite Laboratories knew or should have known of the hazards associated with asbestos-containing joint compound, failed to adequately warn users and bystanders of those hazards, and continued to manufacture and sell a product that posed foreseeable risk of serious injury from inhalation exposure.

Individuals who may have grounds to pursue litigation include:

  • Workers who regularly mixed, applied, or sanded UGL Joint Compound and have been diagnosed with mesothelioma, lung cancer, asbestosis, or related asbestos-caused disease
  • Industrial workers, construction tradespeople, or laborers present in environments where UGL Joint Compound was actively used
  • Family members of deceased individuals whose illness and death were attributed to asbestos exposure from joint compound products

Because UGL Joint Compound claims proceed through litigation rather than trust fund administration, the strength and value of individual claims depend significantly on the quality of exposure documentation, medical evidence, and legal representation. Statutes of limitations for asbestos claims vary by state and typically begin to run from the date of diagnosis or the date a claimant knew or should have known of the connection between their illness and asbestos exposure.

Anyone with a potential UGL Joint Compound asbestos exposure claim is strongly encouraged to consult with an attorney experienced in asbestos litigation as early as possible to preserve legal rights and gather the documentation necessary to support a claim.